D. Boral Capital Reiterates “Buy” Rating for Invivyd (NASDAQ:IVVD)

Invivyd (NASDAQ:IVVD)‘s stock had its “buy” rating reissued by research analysts at D. Boral Capital in a research note issued on Monday,Benzinga reports. They presently have a $9.00 price target on the stock.

IVVD has been the topic of several other research reports. EF Hutton Acquisition Co. I upgraded Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Invivyd in a research report on Tuesday, February 4th. Finally, Morgan Stanley reduced their target price on Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research note on Wednesday, November 20th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Invivyd has an average rating of “Buy” and a consensus price target of $7.89.

Invivyd Stock Up 4.8 %

Shares of NASDAQ IVVD opened at $1.30 on Monday. The business’s 50 day moving average price is $0.82 and its 200 day moving average price is $0.87. The firm has a market cap of $155.51 million, a P/E ratio of -0.66 and a beta of 0.61. Invivyd has a 52 week low of $0.35 and a 52 week high of $4.74.

Insider Activity at Invivyd

In other Invivyd news, Director Terrance Mcguire sold 160,400 shares of the firm’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $0.59, for a total value of $94,636.00. Following the completion of the sale, the director now directly owns 4,202,679 shares of the company’s stock, valued at $2,479,580.61. This trade represents a 3.68 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last ninety days, insiders sold 816,466 shares of company stock valued at $423,214. 17.90% of the stock is owned by insiders.

Institutional Trading of Invivyd

A number of hedge funds and other institutional investors have recently modified their holdings of IVVD. Mithril II GP LP purchased a new position in shares of Invivyd during the 4th quarter worth $4,981,000. State Street Corp boosted its holdings in Invivyd by 3.7% during the 3rd quarter. State Street Corp now owns 1,018,640 shares of the company’s stock valued at $1,039,000 after acquiring an additional 35,904 shares during the period. Deutsche Bank AG boosted its holdings in Invivyd by 35.2% during the 4th quarter. Deutsche Bank AG now owns 874,406 shares of the company’s stock valued at $385,000 after acquiring an additional 227,463 shares during the period. Two Sigma Investments LP boosted its stake in shares of Invivyd by 125.3% in the 4th quarter. Two Sigma Investments LP now owns 367,100 shares of the company’s stock valued at $163,000 after buying an additional 204,188 shares during the period. Finally, Two Sigma Advisers LP boosted its stake in shares of Invivyd by 1,276.5% in the 4th quarter. Two Sigma Advisers LP now owns 304,200 shares of the company’s stock valued at $135,000 after buying an additional 282,100 shares during the period. 70.36% of the stock is owned by institutional investors and hedge funds.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.